Stryker Corporation has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Incompass® Total Ankle System. This new implant is designed for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. The Incompass system integrates advanced technologies from Stryker's existing Inbone® and Infinity® systems into a comprehensive solution for total ankle replacement. Developed using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform, the system offers improved surgical flexibility and efficiency, leveraging data from extensive clinical cases and CT scans.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。